Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia.

Autor: Hashmi SK; Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas., Navai SA; Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas., Chambers TM; Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas., Scheurer ME; Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas., Hicks MJ; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas., Rau RE; Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas., Gramatges MM; Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Feb; Vol. 67 (2), pp. e28063. Date of Electronic Publication: 2019 Nov 17.
DOI: 10.1002/pbc.28063
Abstrakt: Conjugated hyperbilirubinemia (CHB) and liver transaminase elevation are known complications of acute lymphoblastic leukemia (ALL) therapy, but host risk factors are poorly understood. Among 373 children diagnosed with ALL between 2011 and 2016, clinically significant CHB and transaminase elevation were observed in 15 (4.0%) and 12 (3.2%) children, respectively, during induction and consolidation. Body mass index ≥95th percentile (odds ratio 9.20, 95% confidence interval 2.56-32.96) was the only host factor independently associated with CHB, and no host factors were associated with transaminase elevation. Obese patients warrant closer monitoring of hepatic function to facilitate early intervention prior to the development of severe, adverse hepatic events.
(© 2019 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: